Other publication
Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)
Authors: Mummery, C. J.; Börjesson-Hanson, A.; Blackburn, D. J.; Vijverberg, E. G. B.; De Deyn, P. P.; Ducharme, S.; Jonsson, M.; Schneider, A.; Rinne, J. O.; Ludolph, A. C.; Bodenschatz, R.; Kordasiewicz, H.; Swayze, E. E.; Fitzsimmons, B.; Mignon, L.; Moore, K. M.; Yun, C.; Baumann, T.; Li, D.; Norris, D.A.; Crean, R.; Graham, D. L.; Huang, E.; Ratti, E.; Bennett, C. F.; Junge, C.; Lane, R. M.
Publisher: Nature Research
Publication year: 2024
Journal: Nature Medicine
Journal name in source: Nature Medicine
Article number: 304
Volume: 30
ISSN: 1078-8956
eISSN: 1546-170X
DOI: https://doi.org/10.1038/s41591-023-02639-3
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Partially Open Access publication channel
Web address : https://www.nature.com/articles/s41591-023-02639-3
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/181983815
Self-archived copy's licence: CC BY
Self-archived copy's version: Publisher`s PDF
Downloadable publication This is an electronic reprint of the original article. |  |
